Characterization and phase I study of CLR457, an orally bioavailable pan-class I PI3-kinase inhibitor

Background CLR457 is an orally bioavailable pan-phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) inhibitor. Methods CLR457 anti-tumor activity and pharmacokinetics (PK) were characterized by in vitro biochemical assays and in vivo tumor xenografts. A first-in-human study was conducted to determ...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Invest New Drugs
Main Authors: Harding, James J., Bauer, Todd M., Tan, Daniel S. W., Bedard, Philippe L., Rodon, Jordi, Doi, Toshihiko, Schnell, Christian, Iyer, Varsha, Baffert, Fabienne, Radhakrishnan, Rajkumar, Fabre, Claire, Juric, Dejan
Format: Artigo
Jezik:Inglês
Izdano: Springer US 2018
Teme:
Phase I Studies
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6440935/
https://ncbi.nlm.nih.gov/pubmed/30073466
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-018-0627-4
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki